Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

– Pivotal Phase III SUNMO study demonstrated an 11.5 month median progression-free survival – three times longer than R-GemOx – – This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community care – – Results will be submitted to global health authorities including the U.S. Food and Drug Administration – SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the…